Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
Compass Pathways has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare, an editorial recognition of organizations driving advancement in biopharma and healthcare. The release reiterates that COMP360 psilocybin has a rolling NDA submission and review underway with the FDA, backed by three late-stage trials in more than 1,000 treatment-resistant depression patients, with commercial launch preparations targeting a first-half 2027 launch and a late-stage PTSD program also in progress.
Key figures
- Nda status
- rolling NDA submission and review underway with FDA
- Late stage trials
- 3
- Anticipated trd launch
- first-half 2027
- Trd trial participants
- more than 1,000
- Us trd patient population
- approximately 4 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.